Find a Doctor

Johan F. Vansteenkiste
JV
Areas of Expertise

Johan F. Vansteenkiste

University Hospital Ku Leuven
Male

Bio

Johan Vansteenkiste is in Leuven, Belgium. He has been an author on 242 peer reviewed articles and participated in 4 clinical trials in the past 15 years.

Areas of Expertise

Contact

Leuven, BE

Latest Advances

Latest Advance
Study
  • Condition: Exon 14-Mutated or Met-Amplified Non-Small Cell Lung Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Capmatinib
  • Number of Patients: 364
  • Published —
This study tested the safety and efficacy of using capmatinib to treat patients with exon 14-mutated or met-amplified non-small cell lung cancer.
Latest Advance
Study
  • Condition: EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Journal: The New England journal of medicine
  • Treatment Used: Osimertinib
  • Number of Patients: 556
  • Published —
This study reported overall survival for osimertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Latest Advance
Study
  • Condition: Non-Small Cell Lung Cancer
  • Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • Treatment Used: Ceritinib plus Nivolumab
  • Number of Patients: 36
  • Published —
In this study, researchers evaluated the safety and effectiveness of ceritinib plus nivolumab for the treatment of advanced non-small cell lung cancer.
Latest Advance
Study
  • Condition: Stage IV non-small cell lung cancer
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Necitumumab in combination with abemaciclib
  • Number of Patients: 66
  • Published —
The study researched using Necitumumab in combination with abemaciclib to treat stage IV non-small cell lung cancer.
Latest Advance
Study
  • Condition: Stage III Non-Small Cell Lung Cancer (NSCLC)
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Nivolumab added Concurrently to Radiotherapy in a Standard First Line Chemo-Radiotherapy (CRT) Regimen
  • Number of Patients: 82
  • Published —
This study evaluated the safety and effectiveness of nivolumab combined with chemo-radiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC).
Latest Advance
Study
  • Condition: Malignant Pleural Mesothelioma
  • Journal: Investigational new drugs
  • Treatment Used: GSK3052230, an FGF Ligand Trap, in Combination with Pemetrexed and Cisplatin
  • Number of Patients: 36
  • Published —
This study evaluated weekly GSK3052230 added to pemetrexed/cisplatin in patients with treatment-naive, unresectable malignant pleural mesothelioma.
Latest Advance
Study
  • Condition: stage III non-small-cell lung cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Durvalumab after chemoradiotherapy
  • Number of Patients: 713
  • Published —
The purpose of the study was to analyze the effectiveness of Durvalumab after chemoradiotherapy for stage III non-small-cell lung cancer.
Latest Advance
Study
  • Condition: Platinum-treated stage IIIB or IV recurrent advanced non-small-cell lung cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Avelumab versus docetaxel
  • Number of Patients: 792
  • Published —
This multi-site phase III study (JAVELIN Lung 200) investigated the efficacy and safety of avelumab compared to docetaxel for patients with stage IIIB or IV recurrent advanced non-small-cell lung cancer previously treated with platinum based chemotherapy. Researchers assessed overall survival.
Latest Advance
Study
  • Condition: Non-Small-Cell Lung Cancer (NSCLCs)
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Capmatinib (INC280) Plus Gefitinib
  • Number of Patients: 161
  • Published —
This study investigated the safety and effectiveness of capmatinib plus gefitinib in patients with EGFR-mutated (damage to the portion of the DNA in a lung cancer cell which carries the "recipe" for making EGFR epidermal growth factor receptor proteins), MET-dysregulated (overproduction of MET protein) Non-Small-Cell Lung Cancer who experienced disease worsening while receiving EGFR-TKI treatment (medicines that bind to certain parts of the epidermal growth factor receptor and slow down or stop cell growth).
Latest Advance
Study
  • Condition: Non-small-cell lung cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Durvalumab
  • Number of Patients: 444
  • Published —
This study assessed the effect of durvalumab as third-line or later treatment for advanced non-small-cell lung cancer.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Intervention Type: Procedure, Radiation
  • Participants: 39
  • Start Date: January 2021
Local AblativeTherapy for Oligoprogressive Non-Small-Cell Lung Cancer Treated With First-line OSImertinib
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Biological, Drug
  • Participants: 64
  • Start Date: September 10, 2019
An Open-label, Dose-escalation, Phase I/II Study to Assess the Safety, the Tolerability, the Immunogenicity and the Preliminary Clinical Activity of the Therapeutic Cancer Vaccine, PDC*lung01, Associated or Not With Anti-PD-1 Treatment in Patients With Non-small-cell Lung Cancer (NSCLC)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Radiation
  • Participants: 350
  • Start Date: April 16, 2019
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

All Publications
View All

Publication
Study
  • Journal: The New England journal of medicine
  • Published —
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Publication
Study
  • Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • Published —
Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).

Contact

Leuven, BE

Insurance

Contact them to find out if they accept your insurance plan.